Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
J Clin Oncol Testori et al. 26:955
Publisher’s Note
The February 20, 2008, article by Testori et al entitled, “Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group” (J Clin Oncol 26:955–962, 2008) was published online February 15, 2008 with an error. The legend for Figure 4 did not include labels for figure parts A-E, and should have been:
Fig 4. Analyses of hazard ratios (HRs) between vitespen (1+ to 10+ vaccinations) and physician’s choice (PC) arms (overall and by substage; based on a 150-day landmark analysis as in Fig 3). (A) M1a, (B) M1b, (C) M1a + M1b, (D) M1c, and (E) Overall.
Each HR is indicated by a circle situated within its 95% CI (horizontal line). Intersecting vertical lines represent HRs of 1. HRs left of unity represent benefit by vitespen, and HRs right of unit represent benefit by PC.
This has been corrected as of July 28, 2008.
|
